Medicare now lets clinicians bill for antidepressant tapering, and leaves the taper itself undefined
- Source and genre. The Centers for Medicare & Medicaid Services (CMS) issued a three-page FAQ document dated 4 May 2026, "Billing for Supervised Medication Deprescribing Services Under Care Management Codes on the Medicare Physician Fee Schedule (PFS)". It is billing guidance for practitioners who bill Medicare, not a clinical guideline.
- CMS defines deprescribing as "the planned, supervised process of dose reduction or discontinuation of a medication when its continued use may no longer be providing net clinical benefit", and lists psychotropic medications (e.g., antidepressants) among the drug classes covered.
- Deprescribing time can count under existing codes if all other billing requirements are met: chronic care management (CPT 99437, 99439, 99487, 99489, 99490, 99491), principal care management (99424, 99425, 99426, 99427), general behavioral health integration (99484) and psychiatric collaborative care (99492, 99493, 99494). No new code is created. Clinical pharmacist time can count when furnished incident to a physician or non-physician practitioner. Work already paid under Medicare Part D cannot also be billed to the PFS.
- CMS names no single clinical guideline. It expects "evidence-based clinical judgment" and points to guidelines from professional societies, peer-reviewed deprescribing protocols, and FDA-approved drug labeling on recommended tapering schedules.
A three-page CMS question-and-answer document dated 4 May 2026 tells Medicare practitioners that supervised tapering of psychotropic medication, with antidepressants given as the example, can be billed as care management time. It adds no code. It covers clinicians who bill the Medicare Physician Fee Schedule, and it speaks to payment, not to how a taper should be run.
Billing for the work between visits
CMS describes what a deprescribing plan may contain: a tapering schedule, target doses, and contingency plans for symptom recurrence or discontinuation reactions. The activities it lists are monitoring patient-reported symptoms between visits, including withdrawal or discontinuation syndrome and signs of relapse, communicating with the patient, coordinating among prescriber, pharmacist and therapist, and adjusting the schedule through dose holds, slower increments, or temporary dose increases. For SSRIs and other psychiatric medications, the document says the behavioral health integration and collaborative care codes may encompass this work. A clinical pharmacist's time counts when it is incident to a practitioner's services and within state scope of practice.
A taper with no named protocol
On clinical content the document is deliberately open. Most care management codes, CMS says, do not require adherence to any single guideline, and the plan should be individualized. The sources it calls widely recognized are professional society guidelines, peer-reviewed protocols, and FDA labeling on tapering schedules. It does not say which of them applies to which drug.
For the practitioner, the billing permission and the missing standard arrive together. A defensible chart entry names the source the schedule follows, the dose steps and target doses, the criteria for a hold or a slower step, the rating scale used to separate discontinuation symptoms from relapse, and who checks in with the patient between visits. Where the plan departs from the cited source, the reason belongs in the same note.
CMS has agreed to pay for the taper, but it names no protocol for it. The clinician still has to write the plan.
This is billing guidance in FAQ form, issued by a payer, and it is not a clinical guideline or a rule. It does not specify which professional society guideline, protocol or drug label applies to any given medication, and the codes can be billed only if all other requirements of each service are met.